EQS Post-admission Duties announcement: Fresenius Medical Care AG
/ Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014
Fresenius Medical Care AG : Release of a capital market information
23.03.2026 / 15:03 CET/CEST
Dissemination of a Post-admission Duties announcement transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
Fresenius Medical Care AG: Share buyback
Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014
Share buyback – Interim Report
In the period from March 16, 2026, to March 20, 2026 (each inclusive), 1,073,313 shares were bought back within the framework of the second tranche of the share buyback of Fresenius Medical Care AG, the start of which was disclosed on January 12, 2026, pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No. 596/2014, Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052.
Shares were bought back as follows:
Date
Acquired shares (number)
Weighted average price (in EUR)
Transaction volume (in EUR)
Trading venue
16 March 2026
57,000
39.9930
2,279,601.00
XETR
17 March 2026
65,000
39.9250
2,595,125.00
XETR
18 March 2026
225,313
39.2843
8,851,263.49
XETR
19 March 2026
110,000
38.5294
4,238,234.00
CEUX
19 March 2026
190,000
38.6755
7,348,345.00
XETR
20 March 2026
27,000
37.8892
1,023,007.60
AQEU
20 March 2026
137,000
37.8816
5,189,782.90
CEUX
20 March 2026
17,000
37.8918
644,161.34
TQEX
20 March 2026
245,000
37.8799
9,280,581.97
XETR
A total of 7,814,900 shares has been acquired within the framework of the second tranche of the share buyback.
The purchase of the shares is carried out by a credit institution commissioned by Fresenius Medical Care AG.
Fresenius Medical Care AG will provide regular information regarding the progress of the share buyback, including by posting its required disclosures at https://freseniusmedicalcare.com/en/investors/shares/share-buyback/.
23.03.2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News
Fresenius Medical Care AG is the world's leading supplier of services and equipment for patients with kidney problems. Net sales break down by activity as follows:
- clinical care services (75.2%): operated, at the end of 2025, 3,601 institutions;
- manufacturing of dialyzers and related products (24.8%): hemo-dialysis and pediatric dialysis machines, etc. The group also offers therapies accompanied by care and treatment for dialysis patients.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
